Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

David Berry

Noubar Afeyan

Seres Therapeutics, Inc.

IA Electric Vehicles is involved in the sale of electric vans and commercial vehicles, focusing on providing affordable options for businesses.

IA Electric Vehicles

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Metric
Company Name	Seres Therapeutics, Inc.	IA Electric Vehicles
Symbol	MCRB
MSH ID	COM:SERESTHERAPEUTICS	UK:CO:INNOVATION-AUTOMOTIVE
Market	STOCKS	PRIVATE
Sector	Healthcare	Transportation
Industry	Biotechnology	Automotive
Country	US	GB
Stage
Employee Count	233
Website	serestherapeutics.com	innovation-automotive.co.uk
LinkedIn		ia-electric-vehicles
Founders

Metric
Market Cap	149.43M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	126.33M
Revenue (LTM)
Revenue (NTM)
Gross Profit	111.21M
EBITDA	-92.17M
Operating Income	-107.28M
Net Income	-113.72M
EPS	-0.89
Diluted EPS	-0.89
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.94
Operating Profit Margin	-0.62
EBITDA Margin	-0.73
Net Profit Margin	-0.65
Return on Equity	5.37
Return on Assets	-0.24
Return on Capital Employed	-0.33

COM:SERESTHERAPEUTICS

Seres Therapeutics, Inc.

Last Close

0.73

22/11 21:00

Market Cap

156.31M

Beta: -

Volume Today

1.58M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.98
P/B Ratio	-9.25
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	472.63
EV Multiple	0.14

Metric
Days Sales Outstanding	48.36
Days Payables Outstanding	451.86
Days Inventory Outstanding	2.56K
Operating Cycle	20.72K
Cash Conversion Cycle	20.48K
Asset Turnover	0.37

Metric
Operating Cash Flow	-117.35M
Free Cash Flow	-125.33M
Cash Flow to Debt	-0.68
Operating Cash Flow/Sales	-0.60
Free Cash Flow Yield	-0.95

Metric
Cash & Equivalents	127.97M
Accounts Receivable	-8.67M
Inventory	29.65M
Goodwill
Debt to Capitalization	4.78
Debt to Assets	0.58
Current Ratio	2.71
Quick Ratio	1.38

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.29
R&D to Revenue	1.30
SG&A to Revenue	0.73